Related Experiment Video
Updated: Jun 8, 2026

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
Structurally distinct toxicity inhibitors bind at common loci on β-amyloid fibril
Ben Keshet1, Jeffrey J Gray, Theresa A Good
1Department of Chemical and Biochemical Engineering, University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore, Maryland 21250, USA.
Abstract:
The accumulation of aggregated β-Amyloid (Aβ) in the brain is a hallmark of Alzheimer's disease and is thought to play a role in the neurotoxicity associated with the disease. The mechanism by which Aβ aggregates induce toxicity is uncertain. Nonetheless, several small molecules have been found to interact with Aβ fibrils and to prevent their toxicity. In this paper we studied the binding of these known toxicity inhibitors to Aβ fibrils, as a means to explore surfaces or loci on Aβ aggregates that may be significant in the mechanism of action of these inhibitors. We believe knowledge of these binding loci will provide insight into surfaces on the Aβ fibrils important in Aβ biological activity. The program DOCK was used to computationally dock the inhibitors to an Aβ fibril. The inhibitors docked at two shared binding loci, near Lys28 and at the C-termini near Asn27 and Val39. The docking predictions were experimentally verified using lysine specific chemical modifications and Aβ fibrils mutated at Asn27. We found that both Congo red and Myricetin, despite being structurally different, bound at the same two sites. Additionally, our data suggests that three additional Aβ toxicity inhibitors may also bind in one of the sites. Identification of these common binding loci provides targets on the Aβ fibril surface that can be tested in the future for their role in Aβ biological activity.
Insights
Researchers identified key binding sites on amyloid-beta (Aβ) fibrils, crucial for Alzheimer's disease toxicity. Understanding these sites on Aβ aggregates may lead to new therapeutic strategies.
Area of Science:
- Neuroscience
- Biochemistry
- Computational Biology
Background:
- Accumulation of aggregated amyloid-beta (Aβ) is a hallmark of Alzheimer's disease (AD).
- The precise mechanism of Aβ-induced neurotoxicity remains unclear.
- Small molecules inhibiting Aβ fibril toxicity have been identified.
Purpose of the Study:
- To investigate the binding sites of known Aβ toxicity inhibitors on Aβ fibrils.
- To identify significant loci on Aβ aggregates for inhibitor action.
- To gain insight into Aβ fibril surfaces critical for biological activity.
Main Methods:
- Computational docking using the DOCK program to predict inhibitor binding sites on Aβ fibrils.
- Experimental verification using lysine-specific chemical modifications.
- Validation using Aβ fibrils mutated at specific residues (Asn27).
Main Results:
- Two shared binding loci were identified: near Lys28 and at the C-termini (Asn27, Val39).
- Structurally distinct inhibitors (Congo red, Myricetin) bound to the same sites.
- Evidence suggests three additional inhibitors may bind to at least one of these sites.
Conclusions:
- Common binding loci on Aβ fibrils were identified.
- These loci are potential targets for understanding Aβ toxicity mechanisms.
- Further research can explore the role of these binding sites in Aβ's biological activity.
More Related Videos
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Antifungal Agents
Enzyme Inhibition
Alzheimer Disease ll: Pathophysiology
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

